# A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05949606/  
OnCo record `nct05949606` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SI-B001 in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05949606 by Sichuan Baili Pharmaceutical Co., Ltd., with 95 participants enrolled, started 2023-10-30 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001, SI-B003. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05949606
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of SI-B001+SI-B003 With or Without Chemotherapy (SI-B001+SI-B003± Chemotherapy) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT05949606: https://clinicaltrials.gov/study/NCT05949606

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [SI-B001](https://onco.cc/drugs/si-b001/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct05949606.json